Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, UBS Group Analyst Says

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective raised by equities researchers at UBS Group from $42.00 to $48.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 31.62% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 21st. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $42.89.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded down $0.15 during mid-day trading on Friday, reaching $36.47. The stock had a trading volume of 1,320,011 shares, compared to its average volume of 6,959,974. Teva Pharmaceutical Industries has a 12-month low of $18.21 and a 12-month high of $38.37. The company has a market cap of $42.50 billion, a P/E ratio of 60.76, a price-to-earnings-growth ratio of 4.94 and a beta of 0.87. The business has a 50-day simple moving average of $34.58 and a 200 day simple moving average of $33.26. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion for the quarter. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 1.96 earnings per share for the current year.

Insider Activity

In other news, EVP Eliyahu Kalif sold 106,563 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total value of $3,633,798.30. Following the transaction, the executive vice president directly owned 65,621 shares in the company, valued at $2,237,676.10. This trade represents a 61.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.54% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently modified their holdings of TEVA. Aster Capital Management DIFC Ltd bought a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $25,000. Cornerstone Planning Group LLC raised its holdings in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after purchasing an additional 755 shares during the period. Allworth Financial LP boosted its position in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Teva Pharmaceutical Industries by 567.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after buying an additional 1,134 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.